NXN-188
Phase 2Small molecule
NXN-188 is one of 44 small molecule programs targeting Headache. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Bayer Aspirin
BayerPreclinical
Savella
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Adempas
BayerPreclinical
NXN-188
NNeurAxon Inc.
Phase 2
Nitrostat
VViatris Specialty LLC
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Headache1 trial
Migraine1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NXN-188. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNeurAxon Inc.